Evaluation effect of Empagliflozin in psychiatric disorders
- Conditions
- psychiatric disorders.
- Registration Number
- IRCT20180404039187N9
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Aged 18 - 65 years old
Diagnosis of mental disorders with psychosis and psychotic disorders based on DSM-V-TR
Stable treatment with atypical antipsychotics (olanzapine, clozapine and risperidone) in the last 6 months (no dose change in the last 30 days)
Stable body weight (definition: less than 5% weight change in the last three months before the trial)
Body mass index greater than or equal to 25 (BMI=25)
Pregnancy and lactation
A recent history of drug abuse or dependence
Hepatic failure (increase in liver trans aminases to 2 times normal)
Renal insufficiency (GFR less than 30)
Having type 1 or 2 diabetes
Dysfunction of the pancreas
Cardiovascular disease
Uncontrollable blood pressure
Treatment with corticosteroids or other hormone therapy
Use medication to lose weight in the last 3 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FBS. Timepoint: The beginning and the end of the study. Method of measurement: Laboratory tests (enzymatic).;Blood pressure. Timepoint: The beginning of the study, the fourth week, the eighth week and the end of the study. Method of measurement: using a sphygmomanometer.;Body weight. Timepoint: The beginning of the study, the fourth week, the eighth week and the end of the study. Method of measurement: Using digital scale.;Waist circumference. Timepoint: The beginning of the study, the fourth week, the eighth week and the end of the study. Method of measurement: Using a plastic meter.;LDL-HDL-TG. Timepoint: The beginning and the end of the study. Method of measurement: Laboratory tests (enzymatic).
- Secondary Outcome Measures
Name Time Method